These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 15589452

  • 1. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients.
    Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE.
    Joint Bone Spine; 2004 Nov; 71(6):601-3. PubMed ID: 15589452
    [No Abstract] [Full Text] [Related]

  • 2. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
    Titos Arcos JC, Hallal H, Robles M, Andrade RJ.
    Rev Esp Enferm Dig; 2012 May; 104(5):282-4. PubMed ID: 22662786
    [No Abstract] [Full Text] [Related]

  • 3. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
    Francis S, Block MJ.
    Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
    [No Abstract] [Full Text] [Related]

  • 4. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA, Agudo M.
    Med Clin (Barc); 2010 May 22; 134(15):684-5. PubMed ID: 20176386
    [No Abstract] [Full Text] [Related]

  • 5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov 22; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 6. [Anti-TNF therapy in rheumatoid arthritis].
    Yakeuchi T, Amano K.
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb 22; 27(1):7-15. PubMed ID: 15045810
    [No Abstract] [Full Text] [Related]

  • 7. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May 17; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
    Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E.
    Semin Arthritis Rheum; 2013 Oct 17; 43(2):144-51. PubMed ID: 23838092
    [Abstract] [Full Text] [Related]

  • 9. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R, Goldman JA, Leirisalo-Repo M, Zanetakis E, El-Kadi H, Kellner H, Bolce R, DeHoratius R, Wang J, Decktor D.
    Curr Med Res Opin; 2014 Nov 17; 30(11):2139-49. PubMed ID: 25050591
    [Abstract] [Full Text] [Related]

  • 10. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
    Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J, ARTIS Study Group.
    Ann Rheum Dis; 2015 Feb 17; 74(2):354-60. PubMed ID: 24285495
    [Abstract] [Full Text] [Related]

  • 11. [TNF targetting therapy for rheumatoid arthritis].
    Takeuchi T.
    Nihon Naika Gakkai Zasshi; 2006 Sep 10; 95(9):1787-94. PubMed ID: 17037316
    [No Abstract] [Full Text] [Related]

  • 12. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 Sep 10; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 13. Questions and answers in 2008 about biologics in rheumatoid arthritis.
    Weinblatt ME.
    J Rheumatol; 2008 Sep 10; 35(9):1878-81. PubMed ID: 18785296
    [No Abstract] [Full Text] [Related]

  • 14. [Some comments on the PRAXIS study].
    Lizán Tudela L, Sabater Torres FJ.
    Farm Hosp; 2008 Sep 10; 32(3):188-90; author reply 190-3. PubMed ID: 18840353
    [No Abstract] [Full Text] [Related]

  • 15. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.
    Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, Logeart I, Schaeverbeke T, Sibilia J, Le Loët X, Combe B.
    Joint Bone Spine; 2014 Jul 10; 81(4):352-9. PubMed ID: 24721422
    [Abstract] [Full Text] [Related]

  • 16. Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.
    Rose E, Lequerré T, Pouplin S, Daragon A, Le Loët X, Vittecoq O.
    Joint Bone Spine; 2012 Jul 10; 79(4):421-2. PubMed ID: 22512937
    [No Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
    Canhão H, Rodrigues AM, Mourão AF, Martins F, Santos MJ, Canas-Silva J, Polido-Pereira J, Pereira Silva JA, Costa JA, Araújo D, Silva C, Santos H, Duarte C, da Silva JA, Pimentel-Santos FM, Branco JC, Karlson EW, Fonseca JE, Solomon DH.
    Rheumatology (Oxford); 2012 Nov 10; 51(11):2020-6. PubMed ID: 22843791
    [Abstract] [Full Text] [Related]

  • 18. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
    Neovius M, Askling J.
    Ann Rheum Dis; 2014 Jun 10; 73(6):e32. PubMed ID: 24638970
    [No Abstract] [Full Text] [Related]

  • 19. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 10; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 20. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 10; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.